Trade Cellectar Biosciences, Inc. - CLRB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02429% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002068% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.32 |
| Open | 1.33 |
| 1-Year Change | -49.04% |
| Day's Range | 1.24 - 1.33 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 9, 2024 | 1.32 | -0.02 | -1.49% | 1.34 | 1.36 | 1.31 |
| Dec 6, 2024 | 1.36 | 0.01 | 0.74% | 1.35 | 1.38 | 1.34 |
| Dec 5, 2024 | 1.34 | -0.11 | -7.59% | 1.45 | 1.45 | 1.34 |
| Dec 4, 2024 | 1.44 | -0.02 | -1.37% | 1.46 | 1.46 | 1.41 |
| Dec 3, 2024 | 1.44 | -0.07 | -4.64% | 1.51 | 1.51 | 1.40 |
| Dec 2, 2024 | 1.49 | -0.04 | -2.61% | 1.53 | 1.53 | 1.48 |
| Nov 29, 2024 | 1.52 | -0.01 | -0.65% | 1.53 | 1.55 | 1.51 |
| Nov 27, 2024 | 1.51 | -0.01 | -0.66% | 1.52 | 1.57 | 1.50 |
| Nov 26, 2024 | 1.53 | -0.04 | -2.55% | 1.57 | 1.58 | 1.52 |
| Nov 25, 2024 | 1.55 | -0.03 | -1.90% | 1.58 | 1.60 | 1.51 |
| Nov 22, 2024 | 1.56 | 0.03 | 1.96% | 1.53 | 1.59 | 1.50 |
| Nov 21, 2024 | 1.55 | -0.01 | -0.64% | 1.56 | 1.57 | 1.36 |
| Nov 20, 2024 | 1.53 | -0.03 | -1.92% | 1.56 | 1.67 | 1.53 |
| Nov 19, 2024 | 1.58 | -0.15 | -8.67% | 1.73 | 1.73 | 1.54 |
| Nov 18, 2024 | 1.74 | -0.07 | -3.87% | 1.81 | 1.91 | 1.64 |
| Nov 15, 2024 | 1.84 | -0.16 | -8.00% | 2.00 | 2.01 | 1.81 |
| Nov 14, 2024 | 1.98 | -0.10 | -4.81% | 2.08 | 2.08 | 1.96 |
| Nov 13, 2024 | 2.07 | -0.06 | -2.82% | 2.13 | 2.15 | 2.03 |
| Nov 12, 2024 | 2.11 | 0.01 | 0.48% | 2.10 | 2.12 | 2.06 |
| Nov 11, 2024 | 2.10 | 0.00 | 0.00% | 2.10 | 2.17 | 2.06 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cellectar Biosciences, Inc. Company profile
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. Through its Phospholipid drug conjugate (PDC) deliver platform the Company is focused on to develop PDCs that are designed to target cancer cells. The Company's pipeline consists of clinical and pre-clinical product candidates. Its lead PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells. PDC product candidates also include CLR 1900, 2000 and 12120 series of conjugated compounds, which is being researched independently and through partnerships. The CLR 1900 Series is being targeted for solid tumors with a payload that inhibits mitosis a pathway for treating cancers. CLR 2000 Series is a collaborative PDC program with Avicenna Oncology. CLR 12120 Series is a collaborative PDC program with Orano Med for the development of PDCs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cellectar Biosciences Inc revenues was not reported. Net loss increased 60% to $24.1M. Higher net loss reflects Reaserch and development increase of 74% to $17.5M (expense), General and administrative increase of 16% to $5.5M (expense), General and administrative increase from $395K to $1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.43.
Equity composition
Common Stock $.00153 Par, 03/11, 150M auth., 731,576 issd. Insiders own 47.57%. Preferred Stock $.00001 Par, 7K auth., Ser.C 204 issd. Sr E $0.00001 Par, 408.264045 issd., 04/11, 1-for-153 reverse split. 06/14, 1-for-20 Reverse stock split. 03/16 1-for-10 Reverse stock split.
| Industry: | Pharmaceuticals (NEC) |
100 Campus Drive
FLORHAM PARK
NEW JERSEY 07932
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
09:32, 4 December 2024
Silver price forecast 2025 and beyond: Third party price target
Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?
16:00, 3 December 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
16:41, 28 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com